Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; A Gynecologic Oncology Group Study

Gynecologic Oncology

Volumn 122, Issue 1, 2011, Pages 121-126

  Krivak, Thomas C ^a   Darcy, Kathleen M ^b   Tian, Chunqiao ^b,d   Bookman, Michael ^c   Gallion, Holly ^d   Ambrosone, Christine B ^b   Deloia, Julie A ^e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Precision Therapeutics Inc   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

ERCC1; Ovarian cancer; Pharmacogenomics; Polymorphisms; SNPs

Indexed keywords

CARBOPLATIN; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DNA DAMAGE; DNA REPAIR; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DOXORUBICIN; ENDONUCLEASES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TOPOTECAN;

EID: 79957720845     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.03.027     Document Type: Conference Paper

References (37)

1. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-9.
2. Ozols RF, Bundy BN, Greer BE, et al. Gynecologic Oncology Group Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200. (Pubitemid 46606249)
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
4. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-5. (Pubitemid 351413906)
5. Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003;89:S23-8.
6. DeSilva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA intrastrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-90.
7. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian cancer cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000;16:555-60.
8. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003;63:1311-6. (Pubitemid 36348710)
9. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000;60:1305-13.
10. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Canc Inst 1992;84:1512-7.
11. Wei J, Zou Z, Qian X, et al. ERCC1 mRNA levels and survival of advanced gastric patients treated with a modified FOLFOX regimen. Brit J Cancer 2008;98:1398-402. (Pubitemid 351543582)
12. Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 2008;44:54-60. (Pubitemid 350256935)
13. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91. (Pubitemid 34753602)
14. Kim MK, Cho KJ, Kwon GY, et al. Patients with ERCC1- negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 2008;14:4225-31.
15. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Annals Oncol 2007;18:522-8. (Pubitemid 46359633)
16. Cobo M, Isal D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in Non-small-cell lung cancer. J Clin Oncol 2007;25:2747-54. (Pubitemid 47123183)
17. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-304. (Pubitemid 33096777)
18. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-16. (Pubitemid 28041614)
19. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-8. (Pubitemid 24251002)
20. Steffensen KD, Waldstrom M, Jeppesen U, et al. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 2008;18:702-10. (Pubitemid 352020157)
21. Stadlmann S, Dirnhofer S, Guth U, Thies S, Singer G. ERCC1- immunoexpression does not predict platinum-resistance in ovarian cancer. Gynecol Oncol 2007;108:252-3 (letter to editor).
22. Weberpals J, Garbuio K, O'Brien A, et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 2009;124:806-15.
23. Steffensen KD, Waldstrom M, Jakobsen A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 2009;19:820-5.
24. Kang S, Ju W, Kim JW, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinumbased chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 2006;38:320-4. (Pubitemid 44033245)
25. Krivak TC, Darcy KM, Tian C, et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 2008;26:3598-606.
26. Smith S, Su D, Rigault IA, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based chemotherapy. J Clin Oncol 2007;25:5172-9. (Pubitemid 350232247)
27. Kim HS, Kim MK, Chung HH, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009;113:264-9.
28. Marsh S, Paul J, King CR, Gifford G, Mcleod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 2007;25:4528-35. (Pubitemid 350035308)
29. Darcy KM, Tian C, Reed E. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 2007;67:4474-81. (Pubitemid 46815098)
30. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 2009;27:1419-25.
31. Baysal BE, DeLoia JA, Willett-Broziak JE, et al. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol 2004;95:62-9. (Pubitemid 39286278)
32. Viguier J, Boige V, Miguel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-7. (Pubitemid 41262950)
33. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum based chemotherapy. Clin Adv Hematol Oncol 2003;1:162-6.
34. Kamikozuro H, Kuramochi H, Hayashi K, et al. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 2008;32:1091-6.
35. Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006;24:4333-9. (Pubitemid 46630792)
36. Liu D, O'Day SJ, Yang D, et al: Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 11:1237-1246, 200541.37.
37. Woelfelschneider A, Popanda O, Lilla C, et al. A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis 2008;29(9):1758-64.